GlassScriptPhysician profile
Allan B Ohman
NPI 1144281171
$3,595.96
in general payments reported to CMS, 2019-2025
36 companies · $750 in 2025
The $750 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $156 · 2021: $306 · 2022: $430 · 2023: $688 · 2024: $677 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,114.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $459.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $384.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $336.71 | 2022-2025 | |
| Lilly USA, LLC | $316.25 | 2021-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $273.09 | 2019-2024 | Xarelto |
| Abbvie INC. | $192.79 | 2021-2025 | |
| Exact Sciences Corporation | $166.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $151.71 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $140.41 | 2023-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $108.84 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $93.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.95 | 2022-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $80.73 | 2019-2023 | Trintellix |
| Genentech USA, INC. | $75.40 | 2019-2020 | |
| Astellas Pharma US INC | $74.86 | 2021-2025 | Veozah |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Ohman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.